Skip to content
BALCAO · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Nuo Therapeutics, Inc. AURX

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$3.3M
▲ 142.7% YoY
$-2.5M
$-1.1M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We are a commercial-stage medical device company focused on developing and marketing products for chronic wound care primarily within the U.S. Our only significant current commercial offering consists of a point of care technology for the separation of autologous blood to produce a platelet-based therapy for use in the chronic wound care market. The FDA cleared the Aurix System for marketing in 2007 as a device under Section 510(k) of the Federal Food, Drug, and Cosmetic Act (“FDCA”).

Written from the business description in Nuo Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 30 March 2026. Every sentence was checked against that document before publication.

Growth

USD 3.3M
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 3.3 · Net income -2.5
5M10M-20M-40M
201020132017202020232025
Compound annual growth
+209.1%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−76 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -76.0% · Net -75.8%
-1000%-2000%
201020182025
ROE
FY2024 · ROE -299.3%
-100%-200%
201020182025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -438%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -1.1
-10M-20M
201020182025
Net buybacks $M Dividends $M
FY2017 · Dividends · · Net buybacks -2.9
-2M-3M
2017

Total assetsUSD 1.8M
EquityUSD -956,559.00
CashUSD 548,946.00
Current ratio1.06×

Equity funds -52% of total assets.

The 15-year record

15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
AURX, 15-year financial record
Metric 202520242023202220212020201920182017201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.00.0◌◌−0.00.00.00.00.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌−0.0−0.0−0.0◌−0.0−0.0
EPS, diluted $◌◌◌◌−0.030.27−0.05−0.07−1.02−0.42−0.16−0.20−0.24−0.08−0.23
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————
ROE %—−299.3−196.3−212.6————−231.0—−90.4−63.0−95.9——
Shares out B0.050.050.040.040.040.030.020.020.020.130.130.110.090.060.04

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 77 reconciliationsAUDITED

Reconciled in 15 of the 15 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image